MedTrace Logo

Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment

NCT06924229 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-04-11

No results posted yet for this study

Summary

Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment.

Conditions

  • Braest Cancer
  • Dry Eye

Interventions

DRUG

Hormonal treatment

hormonal treatment for breast cancer

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Elshimaa abd almateen A mateen, Doctorate · Sohag University

  • alaa mahmoud m mahmoud · mahmoud

  • mohamed salah hamed s hamed, Doctorate · Sohag University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-01-01
Completion
2025-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06924229 on ClinicalTrials.gov